Elite Pharmaceuticals has been growing earnings at an average annual rate of 6.6%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 36% per year. Elite Pharmaceuticals's return on equity is 54%, and it has net margins of 31%.
Key information
6.59%
Earnings growth rate
5.13%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
35.99%
Return on equity
54.05%
Net Margin
30.98%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Elite Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:ELTP Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
140
43
12
6
30 Sep 25
123
14
12
7
30 Jun 25
105
-11
11
7
31 Mar 25
84
-4
9
8
31 Dec 24
70
-18
9
8
30 Sep 24
71
-6
8
7
30 Jun 24
66
20
8
8
31 Mar 24
57
20
7
7
31 Dec 23
47
16
6
8
30 Sep 23
41
18
5
8
30 Jun 23
35
4
5
6
31 Mar 23
34
4
5
6
31 Dec 22
33
7
6
5
30 Sep 22
33
7
5
4
30 Jun 22
33
7
5
4
31 Mar 22
32
9
4
4
31 Dec 21
29
6
4
5
30 Sep 21
26
6
4
5
30 Jun 21
25
6
4
5
31 Mar 21
25
5
3
5
31 Dec 20
26
7
4
6
30 Sep 20
25
3
4
6
30 Jun 20
22
-1
4
5
31 Mar 20
18
-2
3
6
31 Dec 19
14
-6
3
4
30 Sep 19
12
-6
3
6
30 Jun 19
9
-7
3
8
31 Mar 19
8
-9
3
8
31 Dec 18
8
-9
3
9
30 Sep 18
8
-8
3
9
30 Jun 18
8
-3
3
9
31 Mar 18
7
-4
3
10
31 Dec 17
7
-4
2
10
30 Sep 17
7
-2
3
10
30 Jun 17
8
23
3
9
31 Mar 17
10
25
2
8
31 Dec 16
13
50
3
7
30 Sep 16
13
12
3
9
30 Jun 16
14
-22
3
12
31 Mar 16
12
-10
3
12
31 Dec 15
9
-42
3
15
30 Sep 15
8
16
3
14
30 Jun 15
6
44
3
13
Quality Earnings: ELTP has a high level of non-cash earnings.
Growing Profit Margin: ELTP became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELTP's earnings have grown by 6.6% per year over the past 5 years.
Accelerating Growth: ELTP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ELTP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.8%).
Return on Equity
High ROE: ELTP's Return on Equity (54%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/01 06:39
End of Day Share Price
2026/06/01 00:00
Earnings
2025/12/31
Annual Earnings
2025/03/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elite Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.